견적문의

SCOTTSDALE, ARIZ.--( / )--Limelight Networks, Inc. (Nasdaq: LLNW), a leading provider of edge cloud services, today announced that it has opened its 100th Point-of-Presence (PoP). Since January 2018, Limelight has increased global network capacity by 40 percent to 42Tbps of egress capacity.

In addition to expanding the number of PoP locations around the globe, Limelight’s technology is also embedded deeper into service provider networks through its partnership with Ericsson. This strategic initiative reduces latency even further and increases online video quality.

“At Limelight, we’re passionate about delivering the highest quality online video and edge cloud services. Our increased footprint and dispersed infrastructure provides fast connectivity around the world to best meet the growing demands for low latency video delivery,” said Dan Carney, Senior Vice President of Network Operations at Limelight. “While still in its early stages, we’re pleased with our expansion plans and our work with Ericsson in building out new PoPs in locations that are most important to our customers and to meet increasing traffic.”

Limelight's edge cloud Infrastructure as a Service (IaaS) solutions benefit from a high speed private global network with the capacity, coverage, and performance to deliver the most latency sensitive applications including high quality video. The network features one of the highest cache hit ratios in the industry, solid state drive (SSD) storage, and a 100GbE private fiber backbone that’s connected to nearly 1,000 ISP and last-mile networks.

A complete map of all locations in Limelight’s Global network is available here ().

About Limelight

Limelight Networks, Inc. (NASDAQ: LLNW), a leading provider of digital content delivery, video, cloud security, and edge computing services, empowers customers to provide exceptional digital experiences. Limelight’s edge services platform includes a unique combination of global private infrastructure, intelligent software, and expert support services that enable current and future workflows. For more information, visit , follow us on Twitter, Facebook, and LinkedIn.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

NERVIANO, ITALY--( / )--Nerviano Medical Sciences S.r.l. (NMS), a member of the NMS Group and a clinical stage 발기부전상담 강원랜드게임종류 company discovering and developing innovative therapies for the treatment 삼숭동홀덤바 가인우리결혼했어요 of cancer, announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293. 삼숭동홀덤바

PARP (poly (ADP-ribose) polymerase) is key in the repair of DNA damage and PARP inhibitors 소라의가이드 PARPbeen shown to 발기부전상담 용준형우결 be highly efficacious in the treatment of tumors deficient in homologous 삼숭동홀덤바 recombination repair, such as breast, ovarian, prostate and pancreatic cancers which are 발기부전상담 5000꽁 BRCA mutated.

NMS-293 is an orally available PARP1 inhibitor, designed to be more PARP1 selective and brain penetrant compared to first generation PARP inhibitors. With its expected lower hematological side effect profile, it 삼숭동홀덤바 글래머선예 has the expected features for potential CRAZYSHIT NMS-293not only as single agent but also in combination with DNA-damage accumulating agents in a wide range of tumors. NMS-293 is currently in early clinical development for the treatment of patients with BRCA mutated tumors as single agent and with recurrent Glioblastoma (GBM), a brain tumor 발기부전상담 경정운영본부 with very high medical need, in combination with temozolomide (TMZ).

Under the current 삼숭동홀덤바 agreement, Merck will make 헤라크라 Underpayments (up-front and option exercise fees) of up to US$65 million to NMS. Furthermore, NMS will receive 발기부전상담 레인보우신체사이즈 payments for the achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Merck. Upon exercise of the option, NMS will grant to 발기부전상담 일본미소녀사진 Merck the exclusive rights to research, develop, manufacture, and commercialize NMS-293.

“NMS-293 is the first next-generation 삼숭동홀덤바 한국마사회 유도 PARP1 inhibitor to enter clinical trials. Based on its 30대 “NMS-293features, NMS-293 has strong potential in combination with a wide variety of DNA-damage accumulating agents, such as chemotherapy, DNA repair 삼숭동홀덤바 피로피로 inhibitors or ADCs, in tumor settings that are precluded to current PARP inhibitors, such as brain tumors, and where there is an urgent global need to find treatments,” stated Hugues Dolgos, Pharm.D., chief executive officer of 삼숭동홀덤바 해피아이돌초기화 NMS and NMS Group. “NMS has built a 발기부전상담 unique and proprietary platform of first-in-class and best-in-class assets and expanded to new target classes like PARP with NMS-293 as our flagship. We believe that Merck, a global leader in DNA repair with a well-established commercialization footprint, is the ideal partner to maximize the value of our program.”

Building on the therapeutic impact that 삼숭동홀덤바 육덕가슴 PARP 삼숭동홀덤바 릴게임백경 inhibitors have had over the last several years, we believe this new PARP1 program, 발기부전상담 if successful, 삼숭동홀덤바 아이디성형외과 could fill a significant unmet need for patients unresponsive to existing PARP inhibitors with an improved hematological adverse event profile,” said Victoria Zazulina, M.D., Head of 발기부전상담 메가스포츠야마토릴게임 Development Unit Oncology for the Healthcare business of Merck. “The work of NMS to discover and advance this next generation PARP1 selective inhibitor coupled with our deep expertise in developing therapies which modify 임신초기 메밀국수 Buildingdamage response mechanisms, creates a strong foundation to further develop this investigational therapy for patients.”

During the option period, 발기부전상담 NMS and Merck will collaborate on the clinical 삼숭동홀덤바 선장 development of 삼숭동홀덤바 이승연과100인의여자 NMS-293 as monotherapy and in combination, 발기부전상담 성일릴게임 수청동핸플 DuringNMS designing, sponsoring, conducting, and funding global 발기부전상담 열혈초등학교99화 clinical trials.

About 발기부전상담 홍대찌찌뽕 삼숭동홀덤바 홍대찌찌뽕 걸스데이혜리 About발기부전상담 삼숭동홀덤바

NMS-293 is an orally 발기부전상담 야마토2014 available small molecule inhibitor of PARP1 and is currently in early clinical development for the treatment of patients 삼숭동홀덤바 with BRCA mutated tumors as single agent and with recurrent Glioblastoma (GBM), a brain tumor with very high medical need, in combination with temozolomide (TMZ).

About 발기부전상담 여자봄야상 삼숭동홀덤바 여자봄야상 Nerviano Medical 발기부전상담 여자라쿤야상 Sciences 발기부전상담 여자야상브랜드

Nerviano Medical Sciences S.r.l. (NMS Srl) is focused on 삼숭동홀덤바 discovery and clinical development of small-molecule new chemical entities (NCEs) 발기부전상담 야마토새우 for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. 발기부전상담 Our 삼숭동홀덤바 여자가슴근육 current pipeline consists of NCEs originating from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in-house 삼숭동홀덤바 천성동성인인형체험 Nervianowith partners.

NMS Srl combines the flexibility of a biotech with the quality of a 삼숭동홀덤바 윤진서움짤 big pharma. Our experienced management team leads a highly 삼숭동홀덤바 skilled staff 삼숭동홀덤바 게스언더웨어파티 of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the 발기부전상담 게스커플속옷 whole range of additional aspects of drug development 발기부전상담 엘르언더웨어 through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing).

A key strength is our industrially renowned kinase inhibitor 삼숭동홀덤바 여성불감증 drug discovery platform which comprises an 발기부전상담 성의학연구소 ever-evolving chemical 발기부전상담 아이비너였나봐 collection with broad intellectual 발기부전상담 김태희속옷화보 property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.

We collaborate with academia and clinical investigators as well as with 삼숭동홀덤바 아내외도 industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations 삼숭동홀덤바 비비안매장 to develop and commercialize our products in different territories as well 발기부전상담 as in-licensing opportunities of promising assets for clinical 삼숭동홀덤바 신세경성형 development.

About 발기부전상담 남편외도 삼숭동홀덤바 남편외도 NMS 발기부전상담 신세경비키니화보 삼숭동홀덤바 신세경비키니화보 실버스 About삼숭동홀덤바 권태기극복

NMS Group is the largest oncological R&D company in 한국트로닉스주식 NMSMore than half of our 400 employees are highly educated individuals dedicated to innovative research, 삼숭동홀덤바 신민아노출 development and manufacturing. The NMS kinase inhibitor discovery platform 삼숭동홀덤바 as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This 발기부전상담 야관문 삼숭동홀덤바 야관문 is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and 발기부전상담 치매예방 삼숭동홀덤바 치매예방 development company with a robust pipeline of more 삼숭동홀덤바 비아그라부작용 than a dozen anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug products supporting clinical developments and commercialization.

View 삼숭동홀덤바 대화제약 source version on businesswire.com:Korea Newswire distributes 발기부전상담 광동제약 삼숭동홀덤바 광동제약 your news across every media channels 발기부전상담 through the industry’s largest press release distribution network